Focus: Jasper Therapeutics is a public biotechnology company focused on humanized monoclonal antibodies targeting oncology, dermatology, respiratory, and ophthalmology indications. The company operates as a clinical-stage biotech with a lean pipeline and minimal commercial scale.
Profile data last refreshed 16h ago · AI intelligence enriched 2w ago
Jasper is a pre-revenue clinical biotech with patent protection and public-market access, but severe hiring freeze, opaque pipeline breadth, and accelerating cash burn make it a high-risk early-career or mid-career move absent clarity on clinical near-term catalysts.
Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.
Help build intelligence for Jasper Therapeutics
No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Generated by Claude from Jasper Therapeutics's SEC filings, pipeline programs, hiring velocity, FDA actions, and WARN data. Inference, not editorial — verify before quoting.
Jasper Therapeutics, Inc. Estimates – NASDAQ:JSPR - TradingView
Jasper Therapeutics, Inc. Estimates – NASDAQ:JSPR TradingView
Jasper Therapeutics Completes IgA Nephropathy Enrollment for KP104 Phase 2 Study - The Clinical Trial Vanguard
Jasper Therapeutics Completes IgA Nephropathy Enrollment for KP104 Phase 2 Study The Clinical Trial Vanguard
Kidney study cohort enrollment ends at Jasper Therapeutics (JSPR), with interim data expected by year-end 2026. - Stock Titan
Kidney study cohort enrollment ends at Jasper Therapeutics (JSPR), with interim data expected by year-end 2026. Stock Titan
Jasper Therapeutics, Inc. (JSPR) stock price, news, quote and history - Yahoo Finance UK
Jasper Therapeutics, Inc. (JSPR) stock price, news, quote and history Yahoo Finance UK
All outstanding warrants are eligible for Jasper Therapeutics (JSPR)'s cash purchase offer. - Stock Titan
All outstanding warrants are eligible for Jasper Therapeutics (JSPR)'s cash purchase offer. Stock Titan
Stockholders give Jasper Therapeutics (JSPR) until December 31, 2026 to decide on a reverse split. - Stock Titan
Stockholders give Jasper Therapeutics (JSPR) until December 31, 2026 to decide on a reverse split. Stock Titan
Showing 6 of 10 news items
Based on last 4 crawl cycles
Source: USCIS H-1B Employer Data Hub
Recent peer-reviewed publications with author affiliations at this company
Showing 5 of 9 publications
Upgrade to Pro to access AI interview prep brief and other premium pharma intelligence.
Upgrade to Pro — $25/mo